We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y
Read MoreHide Full Article
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders.
The company has several interesting candidates in its pipeline. Its cancer pipeline comprises enasidenib (IDH2 mutant inhibitor), AG-120 (IDH1 mutant inhibitor) and AG-881 (pan-IDH mutant inhibitor).
With no approved products in its portfolio, revenues at Agios mainly consist of collaboration revenues under its agreement with Celgene Corporation. Agios is in collaboration with Celgene for AG-221 and AG-881.
Agios’ performance so far has been disappointing with the company missing expectations in three of the last four reported quarters. Overall, the company has delivered an average miss of 77.80%.
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Agios Pharmaceuticals, Inc. Price and EPS Surprise
Earnings: Agios posted narrower-than-expected loss in the fourth quarter of 2016. Our consensus called for a loss of $1.55 per share, and the company reported a loss of $1.34.
Revenues: Revenues in the reported quarter also came significantly above expectations. Agios posted revenues of approximately $22.6 million, compared to our consensus estimate of $8 million.
Key Stats: Agios continues to progress with its pipeline. Agios along with Celgene will submitted a new drug application for enasidenib for the treatment of patients with relapsed and/or refractory acute myeloid leukemia in the reported quarter.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on AGIO earnings report later!
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders.
The company has several interesting candidates in its pipeline. Its cancer pipeline comprises enasidenib (IDH2 mutant inhibitor), AG-120 (IDH1 mutant inhibitor) and AG-881 (pan-IDH mutant inhibitor).
With no approved products in its portfolio, revenues at Agios mainly consist of collaboration revenues under its agreement with Celgene Corporation. Agios is in collaboration with Celgene for AG-221 and AG-881.
Agios’ performance so far has been disappointing with the company missing expectations in three of the last four reported quarters. Overall, the company has delivered an average miss of 77.80%.
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Agios Pharmaceuticals, Inc. Price and EPS Surprise
Agios Pharmaceuticals, Inc. Price and EPS Surprise | Agios Pharmaceuticals, Inc. Quote
Earnings: Agios posted narrower-than-expected loss in the fourth quarter of 2016. Our consensus called for a loss of $1.55 per share, and the company reported a loss of $1.34.
Revenues: Revenues in the reported quarter also came significantly above expectations. Agios posted revenues of approximately $22.6 million, compared to our consensus estimate of $8 million.
Key Stats: Agios continues to progress with its pipeline. Agios along with Celgene will submitted a new drug application for enasidenib for the treatment of patients with relapsed and/or refractory acute myeloid leukemia in the reported quarter.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on AGIO earnings report later!
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>